IL17A and chronic obstructive pulmonary disease: Patients with COPD who were treated with simvastatin showed a significant decrease of IL-17A levels compared with the baseline levels prior to treatment, whereas there was no significant reduction in control subjects treated with placebo (median [interquartile range (IQR)], 9.1 pg/mL [5.4-21.2 pg/mL] vs 32.3 pg/mL [14.5-45.5 pg/mL], P = .0001; 22.5 pg/mL [8.0-39.8 pg/mL] vs 20.2 pg/mL [11.6-48.3 pg/mL], P = .48, respectively).